340 related articles for article (PubMed ID: 31082915)
1. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Rivero-Soto RJ; Yu J; Javed AA; Burkhart RA; Rinkes IHMB; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Jun; 269(6):1154-1162. PubMed ID: 31082915
[TBL] [Abstract][Full Text] [Related]
2. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
3. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
[TBL] [Abstract][Full Text] [Related]
5. Resected pancreatic adenocarcinoma: An Asian institution's experience.
Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
7. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
8. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
10. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
11. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
12. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection.
Sahakyan MA; Kim SC; Kleive D; Kazaryan AM; Song KB; Ignjatovic D; Buanes T; Røsok BI; Labori KJ; Edwin B
Surgery; 2017 Oct; 162(4):802-811. PubMed ID: 28756944
[TBL] [Abstract][Full Text] [Related]
15. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?
Parikh AA; Maiga A; Bentrem D; Squires MH; Kooby DA; Maithel SK; Weber SM; Cho CS; Katz M; Martin RC; Scoggins CR; Sutton J; Ahmad SA; Abbott DE; Carr J; Kim HJ; Yakoub D; Idrees K; Merchant N
J Am Coll Surg; 2016 Apr; 222(4):448-56. PubMed ID: 26895735
[TBL] [Abstract][Full Text] [Related]
17. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
[TBL] [Abstract][Full Text] [Related]
18. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
Saeed H; Hnoosh D; Huang B; Durbin EB; McGrath PC; Desimone P; Maynard E; Anthony LB; Dineen SP; Hosein PJ; Tzeng CW
J Surg Oncol; 2016 Sep; 114(4):451-5. PubMed ID: 27238300
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
20. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]